BioAtla, Inc. (BCAB)

NASDAQ: BCAB · IEX Real-Time Price · USD
3.52
+0.58 (19.73%)
Jul 5, 2022 4:00 PM EDT - Market closed

Company Description

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.

Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer.

It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer.

BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

BioAtla, Inc.
Country United States
Founded 2007
IPO Date Dec 16, 2020
Industry Biotechnology
Sector Health Care
Employees 56

Contact Details

Address:
11085 Torreyana Road
San Diego, CA 92121
United States
Phone 858 558 0708
Website bioatla.com

Stock Details

Ticker Symbol BCAB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
IPO Price $18.00
CIK Code 0001826892
ISIN Number US09077B1044
SIC Code 2836

Key Executives

Name Position
Dr. Jay M. Short Ph.D. Co-Founder, Chief Executive Officer and Chairman
Scott Andrew Smith President and Director
Richard A. Waldron Chief Financial Officer
Dr. Eric L. Sievers M.D. Chief Medical Officer
Christian Vasquez Vice President of Finance, Corporate Controller and Secretary
Philippe Martin Chief Clinical Development and Operations
Lisa M. Pelton Accounting Manager
Susie Melody Senior Vice President of Human Resources
Dr. Cathy Chang Ph.D. Senior Vice President of Research & Development
Monica Sullivan Senior Vice President of Intellectual Property and Contracts

Latest SEC Filings

Date Type Title
Jun 23, 2022 4 Statement of changes in beneficial ownership of securities
Jun 22, 2022 4 Statement of changes in beneficial ownership of securities
Jun 17, 2022 4 Statement of changes in beneficial ownership of securities
Jun 17, 2022 4/A Statement of changes in beneficial ownership of securities
Jun 17, 2022 4 Statement of changes in beneficial ownership of securities
Jun 17, 2022 4 Statement of changes in beneficial ownership of securities
Jun 17, 2022 4 Statement of changes in beneficial ownership of securities
Jun 17, 2022 4 Statement of changes in beneficial ownership of securities
Jun 17, 2022 8-K Current report
Jun 10, 2022 SC 13G/A Statement of acquisition of beneficial ownership by individuals